Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.

Andrew R ClampDomenica LorussoAmit M OzaCarol AghajanianAna OakninAndrew DeanNicoletta ColomboJohanne I WeberpalsGiovanni ScambiaAlexandra LearyRobert W HollowayMargarita Amenedo GancedoPeter C FongJeffrey C GohDavid M O'MalleyDeborah K ArmstrongSusana BanerjeeJesus García-DonasElizabeth M SwisherTerri CameronSandra GobleRobert L ColemanJonathan A Ledermann

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2021)

Rucaparib maintenance treatment significantly improved progression-free survival versus placebo irrespective of progression-free interval following penultimate platinum, number of lines of prior chemotherapy, and previous use of bevacizumab.

Keyphrases

phase iii
open label
double blind
clinical trial
phase ii
placebo controlled
free survival
randomized controlled trial
study protocol
squamous cell carcinoma
locally advanced